Digital health company DarioHealth announced Thursday a partnership with a national benefit administrator to provide employers with cardiometabolic support programs, including services for patients using increasingly popular GLP-1 weight loss medications.
The Nasdaq-listed company said the collaboration has already begun generating revenue since January 2025, marking its first partnership with a national benefit administrator.
“We are thrilled to partner with one of the fastest growing benefits administrators in the country to support their goals of delivering market-leading health benefits that help reduce costs associated with healthcare,” said Steven Nelson, chief commercial officer at Dario.
Targeting medication adherence
The partnership aims to address research showing 50-75% of patients discontinue GLP-1 medications within one year without proper behavioral support. Dario’s platform combines AI-driven monitoring with personalized coaching to support patients from medication initiation through long-term weight maintenance.
The benefit administrator selected Dario’s integrated system to help manage rising healthcare costs associated with metabolic conditions including diabetes, pre-diabetes, hypertension and weight management.
Market expansion
The company positioned the collaboration as an entry point into multiple healthcare segments, including the GLP-1 market projected to reach $100 billion by 2030 and the broader cardiometabolic disease market expected to surpass $1.2 trillion by 2033, according to figures cited by the company.
DarioHealth’s platform focuses on chronic condition management through digital therapeutics, offering personalized interventions for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
The partnership allows employers to implement the program outside normal benefit enrollment cycles, which the company said contributed to faster revenue generation in the first quarter of 2025.
